We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LGC Clinical Diagnostics Acquires Urinalysis Quality Controls Provider Kova International

By LabMedica International staff writers
Posted on 25 Jul 2023

LGC Clinical Diagnostics (Middlesex, UK), a business unit of LGC and a leading provider of biological materials and viral antigens, has acquired Kova International, Inc. (Garden Grove, CA, USA), a developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories. Kova has two manufacturing facilities, one focusing on urinalysis quality controls and the other on toxicology quality controls. Both the manufacturing facilities are certified to ISO 13485:2016 quality management system standards and guidelines, as well as cGMP qualified to manufacture quality control products, and are registered FDA manufacturing sites for the clinical diagnostic laboratory industry.

Kova’s quality control products are employed in hospitals, employee wellness programs, forensic testing and medical device manufacturers production and Quality Assurance (QA) programs. The acquisition expands LGC Clinical Diagnostics’ clinical quality control portfolio, complementing its wide range of offerings across biochemistry, serology, molecular, and clinical genomics quality controls and reference materials. LGC Clinical Diagnostics has over 35 years of industry experience and caters to more than 20,000 customers in over 100 counties. The company is keen on combining Kova’s expertise with its own in order to offer its customers unmatched solutions with expanded capabilities.


Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)

“We are excited to bring Kova’s established clinical urinalysis and toxicology quality controls into LGC Clinical Diagnostics,” said Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics. “Kova and LGC Clinical Diagnostics are an excellent fit. Our focus on delivering confidence to clinical laboratories in test precision, accuracy, and conformance to international standards, perfectly aligns us with a common objective of Science for a Safer World.”

Related Links:
LGC
Kova International, Inc.


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests